Valuation dashboard for Kiniksa Pharmaceuticals International, plc (KNSA) with P/E 71.21, P/B 10.27, EV/EBITDA 49.0 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
What would it be worth at its usual multiples?
Versus its usual multiples: expensive · Current P/E 71.2× · Multiples range: $40.20 · $40.20.
At its sector median (30.7×) $40 (-57 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
P/E calculated by Kaplio with 12-month GAAP earnings; the data provider reports 87.2×.
Analysis Summary
Trailing-twelve-month margins: gross margin 54.3%, operating margin 13.8%, net margin 11.6%.
At $93.29 (closing price, November 3, 2026), KNSA trades at a P/E of 71.21 and an ROE of 17.27%. Market capitalisation stands at $7.3B.
Balance sheet quality for KNSA: debt-to-equity ratio of 0.01, current ratio of 3.91 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 71.21 |
| Price / Book | 10.27 |
| EV / EBITDA | 49.0 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals International, plc | $7.3B | 71.21 | 10.27 | 17.3% |
| IMVT | Immunovant, Inc. | $6.0B | 8.12 | -69.6% | |
| DNTH | Dianthus Therapeutics, Inc. | $4.6B | 3.95 | -3.5% | |
| SYRE | Spyre Therapeutics, Inc. | $9.2B | 32.67 | -29.8% | |
| ORKA | Oruka Therapeutics, Inc. | $6.6B | 5.62 | -20.8% | |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | 11.18 | 2.97 | 49.3% |
Price
| Price | $93.29 (closing price, November 3, 2026) |
| Market Cap | $7.3B |
| Exchange | NASDAQ |
| Country | GB |
Profitability
| Return on Equity | 17.27% |
| Return on Invested Capital | 12.30% |
| Return on Assets | 11.14% |
| Gross Margin | 54.26% |
| Operating Margin | 13.79% |
| Net Margin | 11.58% |
Related companies: IMVT · DNTH · SYRE · ORKA · NRIX
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of KNSA: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks